home / stock / sabs / sabs quote
Last: | $4.2499 |
---|---|
Change Percent: | -2.24% |
Open: | $4.1 |
Close: | $4.2499 |
High: | $4.3946 |
Low: | $4.1 |
Volume: | 4,877 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.2499 | $4.1 | $4.2499 | $4.3946 | $4.1 | 4,877 | 04-26-2024 |
$4.01 | $4.01 | $4.01 | $4.01 | $4.01 | 794 | 04-25-2024 |
$4.4 | $4.4001 | $4.4 | $4.4001 | $4.4 | 731 | 04-24-2024 |
$4.36 | $4.38 | $4.36 | $4.39 | $4.36 | 858 | 04-23-2024 |
$4.39 | $4.505 | $4.39 | $4.65 | $4.36 | 1,741 | 04-22-2024 |
$4.29 | $4.31 | $4.29 | $4.31 | $4.29 | 891 | 04-19-2024 |
$4.46 | $4.34 | $4.46 | $4.7062 | $4.34 | 2,927 | 04-18-2024 |
$4.6 | $4.37 | $4.6 | $4.8499 | $4.34 | 3,644 | 04-17-2024 |
$4.88 | $4.94 | $4.88 | $4.94 | $4.5301 | 6,922 | 04-16-2024 |
$4.61 | $4.78 | $4.61 | $4.78 | $4.6 | 3,060 | 04-15-2024 |
$4.675 | $4.61 | $4.675 | $4.675 | $4.5401 | 3,497 | 04-12-2024 |
$4.5 | $4.5 | $4.5 | $4.5 | $4.5 | 688 | 04-11-2024 |
$4.55 | $4.49 | $4.55 | $4.55 | $4.49 | 2,579 | 04-10-2024 |
$4.46 | $4.492 | $4.46 | $4.492 | $4.46 | 1,609 | 04-09-2024 |
$4.46 | $4.25 | $4.46 | $4.46 | $4.25 | 1,014 | 04-08-2024 |
$4.34 | $4.45 | $4.34 | $4.62 | $4.2501 | 4,071 | 04-05-2024 |
$4.42 | $4.5463 | $4.42 | $4.5463 | $4.25 | 9,005 | 04-04-2024 |
$4.46 | $4.834 | $4.46 | $4.857 | $4.46 | 4,288 | 04-03-2024 |
$4.5 | $4.72 | $4.5 | $4.72 | $4.4694 | 8,491 | 04-02-2024 |
$4.29 | $4.51 | $4.29 | $4.51 | $4.26 | 5,424 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Company Name:
SABS Stock Symbol:
NASDAQ Market:
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biop...
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...